4-amino-1-(3-(4-fluorophenoxy)propyl)piperidine | 143922-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-amino-1-(3-(4-fluorophenoxy)propyl)piperidine
• 英文别名: 1-(3-(4-fluorophenoxy)propyl)-4-aminopiperidine；1-[3-[4-fluorophenoxy)propyl]-4-piperidinamine；4-fluorophenoxy propyl-4-amino piperidine；1-[3-(4-Fluorophenoxy)propyl]piperidin-4-amine
• CAS: 143922-25-2
• 化学式: C₁₄H₂₁FN₂O
• mdl: MFCD10033818
• 分子量: 252.332
• InChiKey: VONAKDAYRCRINV-UHFFFAOYSA-N

物化性质

• 沸点：
  373.2±42.0 °C(Predicted)
• 密度：
  1.088±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-amino-1-(3-(4-fluorophenoxy)propyl)piperidine 生成 2-(1-(3-(4-fluorophenoxy)propyl)piperidin-4-yl)-2,3-dihydro-6-nitro-1H-benz[de]isoquinoline-1,3-dione hydrochloride
  参考文献：
  名称：

  Tricyclic compounds acting at serotonin receptor subtypes

  摘要：

  化合物的化学式I：##STR1## 其中Z为CH.sub.2或C.dbd.O；X和Y分别选自氢、卤素、羟基、低烷氧基、低烷基、硝基、氨基、氨基甲酰、(低烷基)氨基、二(低烷基)氨基和(低脂肪酰)氨基；R.sup.1为从式(a)、(b)、(c)、(d)和(e)中选择的基团：##STR2## 其中p为0或1；n为1、2或3；R.sup.2为氢、低烷基、C.sub.3-8环烷基、C.sub.3-8环烷基-C.sub.12烷基，或R.sup.6-C.sub.1-2烷基，其中R.sup.6为噻吩基、吡咯基或呋喃基，可选择地被一个或两个选自低烷基、低烷氧基、三氟甲基或卤素的取代基取代，或者为苯基，可选择地被一个或两个选自C.sub.1-4烷氧基、三氟甲基、卤素、硝基、羧基、酯化羧基和C.sub.1-4烷基的取代基取代，可选择地进一步被羟基、C.sub.1-4烷氧基、羧基、酯化羧基或体内可水解的酰氧基取代；每个R.sup.3独立地选自氢、羟基、烷基和烷氧基；每个R.sup.4独立地选自氢或烷基；R.sup.5为氢、低烷基、C.sub.3-8环烷基、C.sub.3-8环烷基-C.sub.1-2烷基、烯基、炔基或R.sup.7-C.sub.1-3烷基，其中R.sup.7为苯基或苯氧基，可选择地被一个或两个选自C.sub.1-4烷氧基、三氟甲基、卤素、硝基、羧基、酯化羧基和C.sub.1-4烷基的取代基取代，可选择地进一步被羟基、C.sub.1-4烷氧基、羧基、酯化羧基或体内可水解的酰氧基取代；以及其药学上可接受的盐、单体异构体、异构体混合物、制备方法、组合物和使用方法。

  公开号：

  US05202318A1
• 作为产物：
  描述：

  3-(4-氟苯氧基)丙酸 在 sodium hydroxide 、 硼烷 作用下， 以 四氢呋喃 、 吡啶 、 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 乙醇 、 水 为溶剂， 生成 4-amino-1-(3-(4-fluorophenoxy)propyl)piperidine
  参考文献：
  名称：

  5-HT.sub.4 agonists and antagonists

  摘要：

  化合物的化学式为I：##STR1## 被用作5-HT.sub.4受体的拮抗剂和部分激动剂，并提供了治疗由5-HT.sub.4受体功能失调引起或受其影响的疾病的治疗方法。

  公开号：

  US06069152A1

文献信息

• Process for preparing 3-substituted indazoles
  申请人：ELI LILLY AND COMPANY

  公开号：EP0908452A2

  公开（公告）日：1999-04-14

  The invention provides a method of preparing compounds of formula I and VIII: which are useful intermediates to compounds that are used as antagonists and partial agonists for the serotonin receptor 5-HT4.

  本发明提供了一种制备式 I 和 VIII.化合物的方法： 它们是用作 5-HT4 血清素受体拮抗剂和部分激动剂的化合物的有用中间体。
• 5-HT4 Agonists and antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0908459A1

  公开（公告）日：1999-04-14

  Compounds of formula I: are used as antagonists and partial agonists for the serotonin receptor 5-HT4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT4 receptor.

  式 I.化合物 用作血清素受体 5-HT4 的拮抗剂和部分激动剂，并为治疗由 5-HT4 受体功能障碍引起或受其影响的疾病提供治疗方法。
• Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist
  作者：Abd M. Ismaiel、Joseph De Los Angeles、Milt Teitler、Stacy Ingher、Richard A. Glennon

  DOI：10.1021/jm00069a010

  日期：1993.8

  DOM [i.e., 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane] is a 5-HT1C/2 serotonin agonist that exerts stimulus control of behavior in animals. In order to determine if the discriminative stimulus effect of DOM is 5-HT1C- or 5-HT2-mediated, it would be informative to conduct tests of stimulus antagonism with a 5-HT1C- or 5-HT2-selective antagonist. To date, no such agents exist. Although the neuroleptic agent spiperone binds at D2 dopamine receptors and 5-HT1A serotonin receptors, (a) it displays about a 1000-fold selectivity for 5-HT2 versus 5-HT1C sites and (b) it has been used as a ''5-HT2-selective'' antagonist. Because spiperone is a behaviorally disruptive agent, it is not suitable for use in drug-discrimination studies. Using the spiperone molecule as a starting point, a limited structure-affinity investigation was conducted in order to identify a suitable antagonist with high affinity and selectivity for 5-HT2 receptors, and yet an antagonist that might lack the disruptive actions of spiperone. Various modifications of the spiperone molecule were examined, but most resulted in decreased 5-HT2 affinity or in loss of selectivity. One compound, 8-[3-(4-fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one(26), was shown to bind at 5-HT2 sites with high affinity (K(i) = 2 nM) and >2,000-fold selectivity versus 5-HT1C sites. In tests of stimulus antagonism using rats trained to discriminate 1 mg/kg of DOM from saline vehicle, 26 behaved as a potent antagonist (ED50 = 0.003 mg/kg) and lacked the disruptive effects associated with spiperone. As such, (a) it would appear that the DOM stimulus is primarily a 5-HT2-mediated, and not 5-HT1C-mediated, phenomenon, and (b) compound 26 may find application in other pharmacologic investigations where spiperone may not be a suitable antagonist.
• COMPOSES HETEROCYCLIQUES POUR LE TRAITEMENT DE L'ISCHEMIE MYOCARDIQUE
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP0842174A1

  公开（公告）日：1998-05-20
• US5132311A
  申请人：——

  公开号：US5132311A

  公开（公告）日：1992-07-21